Thrombosis Drugs Market – Global Industry Analysis and Forecast (2024 – 2030)


Thrombosis Drugs Market is expected to reach US$ 64.26 Bn. at a CAGR of 9.35% during the forecast period 2030.

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Thrombosis Drugs Market Drivers and Restrains:

Thrombosis drugs are used to prevent or treat the blood clot, which can cause different thrombotic events. The drugs for the treatment of thrombosis contain anticoagulants drugs and thrombin inhibitors drug. These drugs reduce the clotting power of blood and consequently the probabilities of thrombosis events such as pulmonary embolism, atrial fibrillation, and deep vein thrombosis. These drugs are accessible in the form of injection, capsule, and tablet.Thrombosis Drugs MarketTo know about the Research Methodology :- Request Free Sample Report

The growing consumption of alcohol and tobacco with obesity, which adds on a high risk of developing symptoms like high blood pressure on veins for a long period, which leads to several thrombosis related complications. The market for thrombosis drugs is driven by an increasing the burden of cardiovascular disease & trauma cases, rising geriatric population and the increasing R&D expenditure in the field of hematological disorders. Additionally, increasing focus on the development of low-cost drugs and large patient pool contributes to the growth of thrombosis drugs market. Ongoing developments in thrombosis drugs, such as Revo Biologic’s ATryn with continuous infusion of drugs are likely drive the thrombosis drugs market during the forecast period.

The growing occurrences of deep vein thrombosis and research activities to develop innovative drugs provide an opportunity for enhanced and effective treatment, which are expected to support the market growth in the near future. However, side effects allied with thrombosis drugs and lack of awareness about the severity of thrombosis may restraining the market growth at global level. The high price of non-vitamin K oral anticoagulant drugs and the availability of generic drugs are likely to hinder the market growth during the forecast period.

Thrombosis Drugs Market Segment Analysis:

By drug class, the global thrombosis drugs market has been segmented into factor Xa inhibitor, heparin, and P2Y12 platelet inhibitor. The factor Xa inhibitor is expected to grow at the largest CAGR of xx% during the forecast period, owing to the high preference of anti-coagulant drugs. These drugs are mainly used for the prevention and treatment of pulmonary embolism and deep vein thrombosis.

Based on disease type, the global market has been segmented into pulmonary embolism, atrial fibrillation, and deep vein thrombosis. In terms of revenue, the pulmonary embolism segment led the market in 2023. The segment is projected to continue to dominate the market during the forecast period.

Thrombosis Drugs Market Regional Insights:

Geographically, the global thrombosis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest market share in 2023, owing to the high prevalence of cardiovascular diseases, the upsurge in the demand for progressive treatment options, early adoption of new technologies, and presence of main key players in this region. Europe and the Asia-Pacific are largest market of market, owing to the presence of a diversified patient pool, emerging economies, and rise in collaboration of domestic and international companies with campaigns for awareness campaign in these regions, thus driving this market.

A report covers the recent development in market for market i.e. Grifols Therapeutics Inc. is a U.S.-based biotechnology company is expected to launch AT- lll, a new type of human recombinant thrombosis drugs for the indication of cardiac surgery cardiopulmonary bypass. In late 2023, Janssen Pharmaceuticals declared the launch of XARELTO (rivaroxaban) for reducing the sustained risk of recurrent venous thromboembolism (VTE). In September 2014, Mylan Inc., acquired the U.S. Commercialization, advertising, and Intellectual property rights relating to Arixtra (Fonaparinux Sodium) Injection and the Authorized generic of Arixtra from Aspen Global Incorporated. This acquisition enhanced Mylan Inc's expansion opportunities in the U.S. market.

Thrombosis Drugs Market Competitive landscape

Major Key players operating in this market are Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc. Manufacturers in the thrombosis drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global market dynamics, structure by analyzing the market segments, and project the global market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.

Thrombosis Drugs Market Scope : Inquire before buying






Thrombosis Drugs Market




Report Coverage
Details




Base Year:
2023
Forecast Period:
2024-2030




Historical Data:
2018 to 2023
Market Size in 2023:
US $ 34.37 Bn.




Forecast Period 2024 to 2030 CAGR:
9.35%
Market Size in 2030:
US $ 64.26 Bn.




 Segments Covered:
by Drug Class
Factor Xa Inhibitor
Heparin
P2Y12 Platelet Inhibitor




by Disease Type
Pulmonary Embolism
Atrial Fibrillation
Deep Vein Thrombosis




by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies






Thrombosis Drugs Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America

Thrombosis Drugs Market, Key Players:

1. Bayer AG
2. Boehringer Ingelheim GmbH
3. Bristol-Myers Squibb
4. Johnson & Johnson
5. Sanofi
6. Pfizer, Inc.
7. Aspen Pharmacare Holdings
8. AstraZeneca plc,
9. Daiichi Sankyo
10. Baxter International Inc.
11. GlaxoSmithKline plc
12. Janssen Pharmaceuticals
13. Grifols Therapeutics Inc.
14. Mylan Inc.
15. Aurobindo Pharma
16. Biogen
17. DAIICHI SANKYO COMPANY, LIMITED
18. AuroMedics Pharma LLC
19. Vasudha Pharma
20. GoodRx, Inc
21. ITALFARMACO S.p.A
22. Inari Medical, Inc.

Frequently Asked Questions:

1. Which region has the largest share in Global Thrombosis Drugs Market?
Ans: North America region held the highest share in 2023.

2. What is the growth rate of Global Thrombosis Drugs Market?
Ans: The Global Thrombosis Drugs Market is expected to grow at a CAGR of 9.35% during forecast period 2024-2030.

3. What is scope of the Global Thrombosis Drugs market report?
Ans: Global Thrombosis Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Thrombosis Drugs market?
Ans: The important key players in the Global Thrombosis Drugs Market are – Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Johnson & Johnson, Sanofi, Pfizer, Inc., Aspen Pharmacare Holdings, AstraZeneca plc,, Daiichi Sankyo, Baxter International Inc.,

5. What is the study period of this market?
Ans: The Global Thrombosis Drugs Market is studied from 2023 to 2030. 





Global Thrombosis Drugs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Thrombosis Drugs Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Thrombosis Drugs Market Analysis and Forecast
6.1. Global Thrombosis Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Thrombosis Drugs Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Thrombosis Drugs Market Value Share Analysis, by Drug Class
7.4. Global Thrombosis Drugs Market Size (US$ Bn) Forecast, by Drug Class
7.5. Global Thrombosis Drugs Market Analysis, by Drug Class
7.6. Global Thrombosis Drugs Market Attractiveness Analysis, by Drug Class

8. Global Thrombosis Drugs Market Analysis and Forecast, by Disease Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Thrombosis Drugs Market Value Share Analysis, by Disease Type
8.4. Global Thrombosis Drugs Market Size (US$ Bn) Forecast, by Disease Type
8.5. Global Thrombosis Drugs Market Analysis, by Disease Type
8.6. Global Thrombosis Drugs Market Attractiveness Analysis, by Disease Type

9. Global Thrombosis Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Thrombosis Drugs Market Value Share Analysis, by Distribution Channel
9.4. Global Thrombosis Drugs Market Size (US$ Bn) Forecast, by Distribution Channel
9.5. Global Thrombosis Drugs Market Analysis, by Distribution Channel
9.6. Global Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel

10. Global Thrombosis Drugs Market Analysis, by Region
10.1. Global Thrombosis Drugs Market Value Share Analysis, by Region
10.2. Global Thrombosis Drugs Market Size (US$ Bn) Forecast, by Region
10.3. Global Thrombosis Drugs Market Attractiveness Analysis, by Region

11. North America Thrombosis Drugs Market Analysis
11.1. Key Findings
11.2. North America Thrombosis Drugs Market Overview
11.3. North America Thrombosis Drugs Market Value Share Analysis, by Drug Class
11.4. North America Thrombosis Drugs Market Forecast, by Drug Class
11.4.1. Factor Xa Inhibitor
11.4.2. Heparin
11.4.3. P2Y12 Platelet Inhibitor
11.5. North America Thrombosis Drugs Market Value Share Analysis, by Disease Type
11.6. North America Thrombosis Drugs Market Forecast, by Disease Type
11.6.1. Pulmonary Embolism
11.6.2. Atrial Fibrillation
11.6.3. Deep Vein Thrombosis
11.7. North America Thrombosis Drugs Market Value Share Analysis, by Distribution Channel
11.8. North America Thrombosis Drugs Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. North America Thrombosis Drugs Market Value Share Analysis, by Country
11.10. North America Thrombosis Drugs Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Thrombosis Drugs Market Analysis, by Country
11.12. U.S. Thrombosis Drugs Market Forecast, by Drug Class
11.12.1. Factor Xa Inhibitor
11.12.2. Heparin
11.12.3. P2Y12 Platelet Inhibitor
11.13. U.S. Thrombosis Drugs Market Forecast, by Disease Type
11.13.1. Pulmonary Embolism
11.13.2. Atrial Fibrillation
11.13.3. Deep Vein Thrombosis
11.14. U.S. Thrombosis Drugs Market Forecast, by Distribution Channel
11.14.1. Hospital Pharmacies
11.14.2. Retail Pharmacies
11.14.3. Online Pharmacies
11.15. Canada Thrombosis Drugs Market Forecast, by Drug Class
11.15.1. Factor Xa Inhibitor
11.15.2. Heparin
11.15.3. P2Y12 Platelet Inhibitor
11.16. Steel Canada Thrombosis Drugs Market Forecast, by Disease Type
11.16.1. Pulmonary Embolism
11.16.2. Atrial Fibrillation
11.16.3. Deep Vein Thrombosis
11.17. Canada Thrombosis Drugs Market Forecast, by Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Retail Pharmacies
11.17.3. Online Pharmacies
11.18. North America Thrombosis Drugs Market Attractiveness Analysis
11.18.1. By Drug Class
11.18.2. By Disease Type
11.18.3. By Distribution Channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Thrombosis Drugs Market Analysis
12.1. Key Findings
12.2. Europe Thrombosis Drugs Market Overview
12.3. Europe Thrombosis Drugs Market Value Share Analysis, by Drug Class
12.4. Europe Thrombosis Drugs Market Forecast, by Drug Class
12.4.1. Factor Xa Inhibitor
12.4.2. Heparin
12.4.3. P2Y12 Platelet Inhibitor
12.5. Europe Thrombosis Drugs Market Value Share Analysis, by Disease Type
12.6. Europe Thrombosis Drugs Market Forecast, by Disease Type
12.6.1. Pulmonary Embolism
12.6.2. Atrial Fibrillation
12.6.3. Deep Vein Thrombosis
12.7. Europe Thrombosis Drugs Market Value Share Analysis, by Distribution Channel
12.8. Europe Thrombosis Drugs Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Europe Thrombosis Drugs Market Value Share Analysis, by Country
12.10. Europe Thrombosis Drugs Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Thrombosis Drugs Market Analysis, by Country
12.12. Germany Thrombosis Drugs Market Forecast, by Drug Class
12.12.1. Factor Xa Inhibitor
12.12.2. Heparin
12.12.3. P2Y12 Platelet Inhibitor
12.13. Germany Thrombosis Drugs Market Forecast, by Disease Type
12.13.1. Pulmonary Embolism
12.13.2. Atrial Fibrillation
12.13.3. Deep Vein Thrombosis
12.14. Germany Thrombosis Drugs Market Forecast, by Distribution Channel
12.14.1. Hospital Pharmacies
12.14.2. Retail Pharmacies
12.14.3. Online Pharmacies
12.15. U.K. Thrombosis Drugs Market Forecast, by Drug Class
12.15.1. Factor Xa Inhibitor
12.15.2. Heparin
12.15.3. P2Y12 Platelet Inhibitor
12.16. U.K. Thrombosis Drugs Market Forecast, by Disease Type
12.16.1. Pulmonary Embolism
12.16.2. Atrial Fibrillation
12.16.3. Deep Vein Thrombosis
12.17. U.K. Thrombosis Drugs Market Forecast, by Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Retail Pharmacies
12.17.3. Online Pharmacies
12.18. France Thrombosis Drugs Market Forecast, by Drug Class
12.18.1. Factor Xa Inhibitor
12.18.2. Heparin
12.18.3. P2Y12 Platelet Inhibitor
12.19. France Thrombosis Drugs Market Forecast, by Disease Type
12.19.1. Pulmonary Embolism
12.19.2. Atrial Fibrillation
12.19.3. Deep Vein Thrombosis
12.20. France Thrombosis Drugs Market Forecast, by Distribution Channel
12.20.1. Hospital Pharmacies
12.20.2. Retail Pharmacies
12.20.3. Online Pharmacies
12.21. Italy Thrombosis Drugs Market Forecast, by Drug Class
12.21.1. Factor Xa Inhibitor
12.21.2. Heparin
12.21.3. P2Y12 Platelet Inhibitor
12.22. Italy Thrombosis Drugs Market Forecast, by Disease Type
12.22.1. Pulmonary Embolism
12.22.2. Atrial Fibrillation
12.22.3. Deep Vein Thrombosis
12.23. Italy Thrombosis Drugs Market Forecast, by Distribution Channel
12.23.1. Hospital Pharmacies
12.23.2. Retail Pharmacies
12.23.3. Online Pharmacies
12.24. Spain Thrombosis Drugs Market Forecast, by Drug Class
12.24.1. Factor Xa Inhibitor
12.24.2. Heparin
12.24.3. P2Y12 Platelet Inhibitor
12.25. Spain Thrombosis Drugs Market Forecast, by Disease Type
12.25.1. Pulmonary Embolism
12.25.2. Atrial Fibrillation
12.25.3. Deep Vein Thrombosis
12.26. Spain Thrombosis Drugs Market Forecast, by Distribution Channel
12.26.1. Hospital Pharmacies
12.26.2. Retail Pharmacies
12.26.3. Online Pharmacies
12.27. Rest of Europe Thrombosis Drugs Market Forecast, by Drug Class
12.27.1. Factor Xa Inhibitor
12.27.2. Heparin
12.27.3. P2Y12 Platelet Inhibitor
12.28. Rest of Europe Thrombosis Drugs Market Forecast, by Disease Type
12.28.1. Pulmonary Embolism
12.28.2. Atrial Fibrillation
12.28.3. Deep Vein Thrombosis
12.29. Rest Of Europe Thrombosis Drugs Market Forecast, by Distribution Channel
12.29.1. Hospital Pharmacies
12.29.2. Retail Pharmacies
12.29.3. Online Pharmacies
12.30. Europe Thrombosis Drugs Market Attractiveness Analysis
12.30.1. By Drug Class
12.30.2. By Disease Type
12.30.3. By Distribution Channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Thrombosis Drugs Market Analysis
13.1. Key Findings
13.2. Asia Pacific Thrombosis Drugs Market Overview
13.3. Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Drug Class
13.4. Asia Pacific Thrombosis Drugs Market Forecast, by Drug Class
13.4.1. Factor Xa Inhibitor
13.4.2. Heparin
13.4.3. P2Y12 Platelet Inhibitor
13.5. Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Disease Type
13.6. Asia Pacific Thrombosis Drugs Market Forecast, by Disease Type
13.6.1. Pulmonary Embolism
13.6.2. Atrial Fibrillation
13.6.3. Deep Vein Thrombosis
13.7. Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Distribution Channel
13.8. Asia Pacific Thrombosis Drugs Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Country
13.10. Asia Pacific Thrombosis Drugs Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Thrombosis Drugs Market Analysis, by Country
13.12. China Thrombosis Drugs Market Forecast, by Drug Class
13.12.1. Factor Xa Inhibitor
13.12.2. Heparin
13.12.3. P2Y12 Platelet Inhibitor
13.13. China Thrombosis Drugs Market Forecast, by Disease Type
13.13.1. Pulmonary Embolism
13.13.2. Atrial Fibrillation
13.13.3. Deep Vein Thrombosis
13.14. China Thrombosis Drugs Market Forecast, by Distribution Channel
13.14.1. Hospital Pharmacies
13.14.2. Retail Pharmacies
13.14.3. Online Pharmacies
13.15. India Thrombosis Drugs Market Forecast, by Drug Class
13.15.1. Factor Xa Inhibitor
13.15.2. Heparin
13.15.3. P2Y12 Platelet Inhibitor
13.16. India Thrombosis Drugs Market Forecast, by Disease Type
13.16.1. Pulmonary Embolism
13.16.2. Atrial Fibrillation
13.16.3. Deep Vein Thrombosis
13.17. India Thrombosis Drugs Market Forecast, by Distribution Channel
13.17.1. Hospital Pharmacies
13.17.2. Retail Pharmacies
13.17.3. Online Pharmacies
13.18. Japan Thrombosis Drugs Market Forecast, by Drug Class
13.18.1. Factor Xa Inhibitor
13.18.2. Heparin
13.18.3. P2Y12 Platelet Inhibitor
13.19. Japan Thrombosis Drugs Market Forecast, by Disease Type
13.19.1. Pulmonary Embolism
13.19.2. Atrial Fibrillation
13.19.3. Deep Vein Thrombosis
13.20. Japan Thrombosis Drugs Market Forecast, by Distribution Channel
13.20.1. Hospital Pharmacies
13.20.2. Retail Pharmacies
13.20.3. Online Pharmacies
13.21. ASEAN Thrombosis Drugs Market Forecast, by Drug Class
13.21.1. Factor Xa Inhibitor
13.21.2. Heparin
13.21.3. P2Y12 Platelet Inhibitor
13.22. ASEAN Thrombosis Drugs Market Forecast, by Disease Type
13.22.1. Pulmonary Embolism
13.22.2. Atrial Fibrillation
13.22.3. Deep Vein Thrombosis
13.23. ASEAN Thrombosis Drugs Market Forecast, by Distribution Channel
13.23.1. Hospital Pharmacies
13.23.2. Retail Pharmacies
13.23.3. Online Pharmacies
13.24. Rest of Asia Pacific Thrombosis Drugs Market Forecast, by Drug Class
13.24.1. Factor Xa Inhibitor
13.24.2. Heparin
13.24.3. P2Y12 Platelet Inhibitor
13.25. Rest of Asia Pacific Thrombosis Drugs Market Forecast, by Disease Type
13.25.1. Pulmonary Embolism
13.25.2. Atrial Fibrillation
13.25.3. Deep Vein Thrombosis
13.26. Rest of Asia Pacific Thrombosis Drugs Market Forecast, by Distribution Channel
13.26.1. Hospital Pharmacies
13.26.2. Retail Pharmacies
13.26.3. Online Pharmacies
13.27. Asia Pacific Thrombosis Drugs Market Attractiveness Analysis
13.27.1. By Drug Class
13.27.2. By Disease Type
13.27.3. By Distribution Channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Thrombosis Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Thrombosis Drugs Market Overview
14.3. Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Drug Class
14.4. Middle East & Africa Thrombosis Drugs Market Forecast, by Drug Class
14.4.1. Factor Xa Inhibitor
14.4.2. Heparin
14.4.3. P2Y12 Platelet Inhibitor
14.5. Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Disease Type
14.6. Middle East & Africa Thrombosis Drugs Market Forecast, by Disease Type
14.6.1. Pulmonary Embolism
14.6.2. Atrial Fibrillation
14.6.3. Deep Vein Thrombosis
14.7. Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Distribution Channel
14.8. Middle East & Africa Thrombosis Drugs Market Forecast, by Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Country
14.10. Middle East & Africa Thrombosis Drugs Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Thrombosis Drugs Market Analysis, by Country
14.12. GCC Thrombosis Drugs Market Forecast, by Drug Class
14.12.1. Factor Xa Inhibitor
14.12.2. Heparin
14.12.3. P2Y12 Platelet Inhibitor
14.13. GCC Thrombosis Drugs Market Forecast, by Disease Type
14.13.1. Pulmonary Embolism
14.13.2. Atrial Fibrillation
14.13.3. Deep Vein Thrombosis
14.14. GCC Thrombosis Drugs Market Forecast, by Distribution Channel
14.14.1. Hospital Pharmacies
14.14.2. Retail Pharmacies
14.14.3. Online Pharmacies
14.15. South Africa Thrombosis Drugs Market Forecast, by Drug Class
14.15.1. Factor Xa Inhibitor
14.15.2. Heparin
14.15.3. P2Y12 Platelet Inhibitor
14.16. South Africa Thrombosis Drugs Market Forecast, by Disease Type
14.16.1. Pulmonary Embolism
14.16.2. Atrial Fibrillation
14.16.3. Deep Vein Thrombosis
14.17. South Africa Thrombosis Drugs Market Forecast, by Distribution Channel
14.17.1. Hospital Pharmacies
14.17.2. Retail Pharmacies
14.17.3. Online Pharmacies
14.18. Rest of Middle East & Africa Thrombosis Drugs Market Forecast, by Drug Class
14.18.1. Factor Xa Inhibitor
14.18.2. Heparin
14.18.3. P2Y12 Platelet Inhibitor
14.19. Rest of Middle East & Africa Thrombosis Drugs Market Forecast, by Disease Type
14.19.1. Pulmonary Embolism
14.19.2. Atrial Fibrillation
14.19.3. Deep Vein Thrombosis
14.20. Rest of Middle East & Africa Thrombosis Drugs Market Forecast, by Distribution Channel
14.20.1. Hospital Pharmacies
14.20.2. Retail Pharmacies
14.20.3. Online Pharmacies
14.21. Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis
14.21.1. By Drug Class
14.21.2. By Disease Type
14.21.3. By Distribution Channel
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Thrombosis Drugs Market Analysis
15.1. Key Findings
15.2. South America Thrombosis Drugs Market Overview
15.3. South America Thrombosis Drugs Market Value Share Analysis, by Drug Class
15.4. South America Thrombosis Drugs Market Forecast, by Drug Class
15.4.1. Factor Xa Inhibitor
15.4.2. Heparin
15.4.3. P2Y12 Platelet Inhibitor
15.5. South America Thrombosis Drugs Market Value Share Analysis, by Disease Type
15.6. South America Thrombosis Drugs Market Forecast, by Disease Type
15.6.1. Pulmonary Embolism
15.6.2. Atrial Fibrillation
15.6.3. Deep Vein Thrombosis
15.7. South America Thrombosis Drugs Market Value Share Analysis, by Distribution Channel
15.8. South America Thrombosis Drugs Market Forecast, by Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies

15.9. South America Thrombosis Drugs Market Value Share Analysis, by Country
15.10. South America Thrombosis Drugs Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Thrombosis Drugs Market Analysis, by Country
15.12. Brazil Thrombosis Drugs Market Forecast, by Drug Class
15.12.1. Factor Xa Inhibitor
15.12.2. Heparin
15.12.3. P2Y12 Platelet Inhibitor
15.13. Brazil Thrombosis Drugs Market Forecast, by Disease Type
15.13.1. Pulmonary Embolism
15.13.2. Atrial Fibrillation
15.13.3. Deep Vein Thrombosis
15.14. Brazil Thrombosis Drugs Market Forecast, by Distribution Channel
15.14.1. Hospital Pharmacies
15.14.2. Retail Pharmacies
15.14.3. Online Pharmacies
15.15. Mexico Thrombosis Drugs Market Forecast, by Drug Class
15.15.1. Factor Xa Inhibitor
15.15.2. Heparin
15.15.3. P2Y12 Platelet Inhibitor
15.16. Mexico Thrombosis Drugs Market Forecast, by Disease Type
15.16.1. Pulmonary Embolism
15.16.2. Atrial Fibrillation
15.16.3. Deep Vein Thrombosis
15.17. Mexico Thrombosis Drugs Market Forecast, by Distribution Channel
15.17.1. Hospital Pharmacies
15.17.2. Retail Pharmacies
15.17.3. Online Pharmacies
15.18. Rest of South America Thrombosis Drugs Market Forecast, by Drug Class
15.18.1. Factor Xa Inhibitor
15.18.2. Heparin
15.18.3. P2Y12 Platelet Inhibitor
15.19. Rest of South America Thrombosis Drugs Market Forecast, by Disease Type
15.19.1. Pulmonary Embolism
15.19.2. Atrial Fibrillation
15.19.3. Deep Vein Thrombosis
15.20. Rest of South America Thrombosis Drugs Market Forecast, by Distribution Channel
15.20.1. Hospital Pharmacies
15.20.2. Retail Pharmacies
15.20.3. Online Pharmacies
15.21. South America Thrombosis Drugs Market Attractiveness Analysis
15.21.1. By Drug Class
15.21.2. By Disease Type
15.21.3. By Distribution Channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Bayer AG
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Boehringer Ingelheim GmbH
16.3.3. Bristol-Myers Squibb
16.3.4. Johnson & Johnson
16.3.5. Sanofi
16.3.6. Pfizer, Inc.
16.3.7. Aspen Pharmacare Holdings
16.3.8. AstraZeneca plc,
16.3.9. Daiichi Sankyo
16.3.10. Baxter International Inc.
16.3.11. GlaxoSmithKline plc
16.3.12. Janssen Pharmaceuticals
16.3.13. Grifols Therapeutics Inc.
16.3.14. Mylan Inc.
16.3.15. Aurobindo Pharma
16.3.16. Biogen
16.3.17. DAIICHI SANKYO COMPANY, LIMITED
16.3.18. AuroMedics Pharma LLC
16.3.19. Vasudha Pharma
16.3.20. GoodRx, Inc
16.3.21. ITALFARMACO S.p.A
16.3.22. Inari Medical, Inc.

17. Primary Key Insights
  • INQUIRE BEFORE BUYING